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Background: Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant and only autonomously active
family of non-LTR retrotransposons in the human genome, expressed not only in the germ lines but also in somatic
tissues. It contributes to genetic instability, aging, and age-related diseases, such as cancer. Our previous study
identified in human gastric adenocarcinoma an upregulated transcript GCRG213, which shared 88% homology with
human L1 sequence and contained a putative conserved apurinic/apyrimidinic endonucleas1 domain.
Methods: Immunohistochemistry was carried out by using a monoclonal mouse anti-human GCRG213 protein
(GCRG213p) antibody produced in our laboratory, on tissue microarray constructed with specimens from 175 gastric
adenocarcinoma patients. The correlation between GCRG213p expression and patient clinicopathological parameters
was evaluated. GCRG213p expression in gastric cancer cell lines were studied using Western blotting analysis. L1
promoter methylation status of gastric cancer cells was tested using methylation-specific PCR. BLASTP was used at the
NCBI Blast server to identify GCRG213p sequence to any alignments in the Protein Data Bank databases.
Results: Most primary gastric cancer, lymph node metastases and gastric intestinal metaplasia glands showed positive
GCRG213p immunoreactivity. High GCRG213p immunostaining score in the primary gastric cancer was positively
correlated with tumor differentiation (well differentiated, p = 0.001), Lauren’s classification (intestinal type, p < 0.05) and
a late age onset of gastric adenocarcinoma (≥65 yrs; p < 0.05). GCRG213p expression has no association with other
clinicopathological parameters, including survival. Western blotting analysis of GCRG213p expression in gastric cancer
cells indicated that GCRG213p level was higher in gastric cancer cell lines than in human normal gastric epithelium
immortalized cell line GES-1. Partial methylation of L1 in gastric cancer cells was confirmed by methylation-specific PCR.
BLASTP program analysis revealed that GCRG213p peptide shared 83.0% alignment with the C-terminal region of L1
endonuclease (L1-EN). GCRG213p sequence possesses the important residues that compose the conserved features
of L1-EN.
Conclusions: GCRG213p could be a variant of L1-EN, a functional member of L1-EN family. Overexpression of
GCRG213p is common in both primary gastric cancer and lymph node metastasis. These findings provide evidence of
somatic L1 expression in gastric cancer, and its potential consequences in the form of tumor.
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Long interspersed nuclear element-1 (LINE-1 or L1) is
the most abundant and only autonomously active family
of non-LTR retrotransposons in the human genome and
comprises about 17% of the human genome [1]. The vast
majority of the approximately 500,000 total copies of L1
in the human genome are not capable of transposition on
their own due to various mechanisms like truncations and
inactivating mutations. However, an estimated 80–100
full-length, retrotransposition competent L1s (RC-L1s) are
present in a typical diploid human genome, and a small
number, termed “hot L1s” exhibit high retrotransposition
efficiencies [2].
Human RC-L1s are about 6.5 kb and encode two pro-
teins (ORF1p and ORF2p) required for retrotransposition
[3]. ORF1p is a 40-kDa protein with RNA binding [4] and
nucleic acid chaperone activities [5]. ORF2p is a 150-kDa
protein with endonuclease (L1-EN) [6] and reverse tran-
scriptase (L1-RT) [7] activities. L1 element may integrate
into several hundred thousand genomic locations, at a
loosely defined consensus site (5′-TTTT/AA-3′), which is
nicked by L1-EN [8]. The host limits the spread of
such elements by transcriptional and post-transcriptional
silencing mechanisms that reduce activity to tolerable
levels [9].
L1 expressed not only in the germ lines but also in
somatic tissues. It is suggested that even low levels of
somatic DNA damage due to L1 activity have the poten-
tial to contribute to genetic instability, aging, and age-
related diseases, such as cancer [10,11]. L1-ORF1 and
ORF2 were upregulated in a variety of malignancies,
such as breast cancer, pancreatic cancer and malignant
germ cell tumors, etc. [12-14]. L1 hypomethylation was
observed in a variety of malignancies such as head and
neck, esophageal and stomach cancers, and in premalig-
nant lesions [15,16]. The degree of L1 hypomethylation
was also associated with a more advanced stage and
poorer prognosis [17,18].
L1-induced influence to cells is not likely limited only
to fully active elements. Even L1 elements with defective
ORF1 coding regions might make an RNA that splices
to express a functional ORF2 with a number of negative
consequences for the cell [19]. Many tissues produce
translatable spliced ORF2 (SpORF2) transcript [20]. A
spliced L1 transcript which includes integrant reverse
transcriptase sequence of ORF2, was found to be essen-
tial for human hepatoma cell proliferation [21].
Our previous study [22] identified an upregulated tran-
script, named gastric cancer related gene 213 (GCRG213),
in human gastric adenocarcinoma. BLAST analysis of
GCRG213 sequence indicated 88% homology with human
LI and revealed a putative conserved domain, apurinic/
apyrimidinic endonucleas1 (APE), in GCRG213-ORF. Our
latest search of the updated GenBank database showsGCRG213-ORF contains a L1-EN conserved domain. This
paper reports our present study that has confirmed the
GCRG213 protein (GCRG213p) expression in gastric can-
cer cell lines by using monoclonal mouse anti-GCRG213p
antibody produced in our laboratory (Geriatric institute,
China PLA General Hospital, Beijing, China). Addi-
tionally, immunohistochemistry (IHC) applied on tissue
microarray (TMA) was used to evaluate GCRG213p
expression in gastric cancer and normal gastric mucosa.
Further analyses were performed to see if there is any
correlation between GCRG213p expression and clinico-
pathological parameters and survival.
Methods
Patients
Patients who underwent gastrectomy for gastric cancer in
PLA general hospital, Beijing, China from 1991 to 2003
were considered candidates for this study. The sampling
criteria were as follows: gender (males or females), age
(20 years or older); newly diagnosed (incident) gastric car-
cinoma without prior treatment; diagnosis histologically
confirmed; paraffin embedded tumor, paired surrounding
non-tumoral gastric mucosa tissues available, with carci-
nomas metastatic to lymph node if possible; and positive
follow-up results at the time of TMA construction. As a
result, 175 cases were recruited in this study, comprising
144 men and 31 women (27 ~ 84 years, mean = 58.58 years).
Among them, sixty seven cases have carcinomas accom-
panied with lymph node metastasis, and six cases of
formalin-fixed, paraffin-embedded normal gastric tissues
were also obtained from non-tumor patients who were
operated on because of benign gastric diseases.
Demographic, lifestyle and clinicopathological data for
the sample cases were shown in Table 1. All tumors were
classified and staged according to the revised guidelines
advocated by the International Union against Cancer. The
follow-up was made to assess their latest conditions in
2005 by consulting their case documents or through phone
calls to patients (or their family members, or family practi-
tioners). A minimal interval of 18 months was adopted,
and the median follow-up time for patients who were still
alive by the end of 2005 was 46 months (the range was
from the minimum 18 to the maximum 129 months).
Survival time was calculated from the date of surgery to
the date of death or the date last known alive.
Permission was given by the ethical committee of the
PLA General Hospital, Beijing, China to use the tissue
and the data for this project. Informed consent was also
obtained from the patients.
Tissue microarray construction, GCRG213p
immunohistochemical staining and assessment
The tissue microarrays (TMAs) were constructed as
described previously [23]. From the samples available,
Table 1 Clinicopathological parameters of gastric cancer







Male 144(82.28%) 31 113 0.111
Female 31(17.72%) 11 20
Age
<65 year 104(59.43%) 31 73 0.029
≥65 year 71(40.57%) 11 60
Smoking
Yes 45(27.27%) 7 38 0.278
No 120(72.73%) 30 90
Drinking
Yes 28(16.97%) 2 26 0.060
No 137(83.03%) 35 102
Family history
of tumor
Yes 14(8.43%) 2 12 0.639
No 152(91.57%) 36 116
Tumor location
Cardiac 48(27.43%) 8 40 0.360
Body 37(21.14%) 10 27
Antrum 90(51.43%) 24 66
Tumor size (cm)
≤1 11(6.29%) 3 8 0.506
1-3 42(24.00%) 13 29
>3 122(69.71%) 26 96
Depth of invasion
T1 46(26.28%) 12 34 0.635
T2 21(12.00%) 7 14
T3 33(18.86%) 6 27
T4 75(42.86%) 17 58
Lymph node
involvement
Yes 75(42.86%) 16 59 0.592
No 100(57.14%) 26 74
Grade of tumor
differentiation
Well 10(5.71%) 0 10 0.001
Moderate 40(22.86%) 4 36
Poor 103(58.86%) 27 76
Signet ring cell 22(12.57%) 11 11
Tumour stage (TNM)
0 21(12.00%) 3 18 0.217
Ia 14(8.00%) 6 8
Table 1 Clinicopathological parameters of gastric cancer
patients studied in tissue microarray (Continued)
Ib 41(23.43%) 10 31
II 60(34.29%) 17 43
IIIa 39(22.28%) 6 33
Lauren’s classification
Intestinal type 153(87.43%) 31 122 0.015
Diffuse type 22(12.57%) 11 11
Resection margin
Presence 6(3.43%) 0 6 0.361
Absence 169(96.57%) 42 127
Microvascular invasion
Presence 20(11.43%) 5 15 0.911
Absence 155(88.57%) 37 118
Status
alive 121(71.18%) 30 91 0.483
dead 49(28.82%) 9 40
5 year survival
<5 yr 47(43.93%) 12 48 0.871
> = 5 yr 60(50.07%) 10 37
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cases with tumor, normal and lymph node tissues if
available.
Antigen retrieval of TMA slides, and formalin-fixed,
paraffin-embedded tissue sections were performed by
pressure cooker treatment for 10 min in an antigen
retrieval solution (10 mmol/L sodium citrate buffer,
pH 6.0). Monoclonal mouse anti human GCRG213p
antibody, which was produced in our laboratory [24],
was added at a dilution of 1:200 and incubated for 2 hr
at room temperature. The slides were then incubated for
1 h in secondary antibody. An EnVision kit (Dako,
Carpinteria, CA, USA) was used to visualize antibody
binding, and slides were subsequently counterstained
with hematoxylin. A PBS-only staining sample was used
as a background control.
Specific yellow-brown immunostaining for GCRG213p
was exclusively located in the cytoplasm. It was scored
independently and in a blinded manner by two inves-
tigators (GJ and XL). The inter-observer disagreements
(approximately 6% of total cases) were reviewed for a
second time, followed by a conclusive judgment by both
observers. Formal scoring was subsequently carried out
by one investigator (WG). The staining intensity was
categorized as 0 (absent), 1 (weak), 2 (moderate), and 3
(strong). The percentage of positively stained cells was
scored as 0 (0% positive), 1 (1-30%), 2 (31-60%), and 3
(>60%). Combined assessing of staining intensity and
extension was used to evaluate GCRG213p expression.
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sion) was 0, and the maximum was 6 [25]. Overall score
of ≥2 was deemed GCRG213p positive.
Western blotting analysis
Gastric cancer cell lines including SGC-7901, BGC-823
and human normal gastric epithelium immortalized cell
line GES-1 were cultured, collected and lysed with the
RIPA buffer on ice before being subjected to Western
blotting analysis. The protein concentration was detec-
ted by the Bradford method with BSA (Sigma-Aldrich)
as the standard. Equal amounts of cell extract (40 μg)
were subjected to 8% SDS-PAGE and transferred to
polyvinylidene difluoride membrane (Bio-Rad) for anti-
body blotting. The membrane was then blocked, incu-
bated with mouse anti-GCRG213p antibody (1:500) for
2 hr at room temperature, followed by incubation with a
horseradish peroxidase–conjugated secondary antibody
for 1 hr at room temperature. The signal was visualized
with an enhanced chemiluminescence detection reagent.
The mouse anti–β-actin antibody (1: 5,000, Sigma) was
detected simultaneously as a loading control.
Detection of methylation status of LINE-1 with MSP
Validation of LINE-1 methylation status was carried out
using methylation-specific PCR (MSP). Total DNA of
SGC-7901, BGC-823, MGC803 and GES-1 cells was
extracted according to the instructions of DNA extraction
kit. The DNA was bisulfite modified as described previ-
ously [26] for 16 hr at 50°C. Bisulfite-converted DNA was
PCR-amplified using Taq polymerase (Invitrogen, USA).
Primers used were [27]:
LINEa: unmethylated LINE-1 forward primer,
TGTGTGTGAGTTGAAGTAGGGT;
LINEb: unmethylated LINE-1 reverse primer,
ACCCAATTTTCCAAATACAACCATCA;
LINEc: methylated LINE-1 forward primer,
CGCGAGTCGAAGTAGGGC;
LINEd: methylated LINE-1 reverse primer,
ACCCGATTTTCCAAATACGACCG.
PCR amplification conditions were: 4°C,5 min;
94°C,30s,58°C,45s,72°C,61s,40 cycles; 72°C,10 min. The
resulting PCR products were visualized on a 2% agarose
gel. Methylated DNA Standards from Zymo Research
were used as positive control, double distilled water as
negative control.Sequence similarity and conserved domain search
PSI-Blast was used at the NCBI Blast server [28] (search
date: 20th January 2012) to identify GCRG213p sequence
to any alignments in the Protein Data Bank databasesincluding all non-redundant GenBank CDS translations,
PDB, SwissProt, PIR and PRF. It was performed with a
standard initial BLASTP search.
Statistical analysis
Chi-square test or fisher’s exact probability was employed
to evaluate the relationship between GCRG213p expres-
sion and clinicopathological variables. Overall survival was
examined by GCRG213p expression with Kaplan-Meier
curves. All p values were two sided and considered
statistically significant if p < 0.05. Statistical analysis was
performed using SPSS 13.0 for Windows (SPSS Inc.,
Chicago, IL).
Results
GCRG213p expression patterns in normal gastric mucosa
and gastric adenocarcinoma
Distinct GCRG213p staining was observed in primary
gastric adenocarcinomas, lymph node metastasis tumors,
and non-tumoral gastric mucosa (Figure 1). In the non-
tumoral gastric mucosa from esopheageal-gastric junc-
tion and antrum area, the cytoplasm of differentiated
surface epithelia and mucosal glands showed negative
staining, but positive GCRG213p staining was observed
in the basal membrane of the normal glands. 133 of 175
primary gastric adenocarcinomas, and 51 of 67 tumors
metastatic to lymph node showed positive GCRG213p
immunoreactivity, which was located in the cytoplasm of
the carcinoma cells.
According to the Lauren classification, gastric cancer
is devided into two histological types: intestinal-type or
diffuse-type. We have 153 intestinal-type cases and 22
diffuse-tye cases in this study. Among the 153 intestinal-
type cases, 34 intestinal metaplasia and 28 intraepithelial
neoplasia samples adjecent to the cancer were identified.
The age (year, mean ± SD) of the intestinal-type group
with intestinal metaplasia (59.67 ± 12.30) was older than
the diffuse-type group (51.05 ± 11.29) (p = 0.004). 31 of
34 intestinal metaplasia, and 27 of 28 low-/high- grade
intraepithelial neoplasia showed GCRG213p immunore-
activity. Most of the positive cases showed mild to
moderate staining (Table 2).
Association between GCRG213 expression and
clinicopathological parameters
High GCRG213p immunostaining score in the primary
gastric cancer was positively correlated with tumor diffe-
rentiation (p = 0.001) (Figure 2). Meanwhile, GCRG213p
expression was correlated with Lauren’s classification
(p < 0.05). The percentage of positive GCRG213p staining
in the aged group (> = 65 yr) was higher than that in the
non-aged group (<65 yr) (60/71 = 84.51% vs. 73/104 =
70.19%, p < 0.05). However, GCRG213p expression was
not found to be associated with other clinicopathological
Figure 1 GCRG213p expression in human malignant and
non-malignant gastric mucosa. Both (A) primary gastric
adenocarcinoma (100×) and (B) adenocarcinoma invaded into the
lymph node (100×) showed positive GCRG213p stainging in the
cytoplasm; (A’) and (B’) demonstrated the higher magnification
(400×) from the area in (A) and (B). (C) In the non-malignant gastric
epithelia, positive staining was observed in the basal membrane but
not in the cytoplasm; GCRG213p immunoreactivity was detected in
the cytoplasm of gastric intestinal metaplasia glands (arrowed)
(100×); (C’) demonstrated the higher magnification (400×) from the
area in (C).
Table 2 GCRG213 expression in gastric tissue samples
Groups Number
non-tumoral gastric epithelia 112
Intestinal metaplasia 34
Low-/high-grade intraepithelial neoplasia 28
adenocarcinoma without LNM † 100
adenocarcinoma with LNM 75
tumor metastatic to lymph node 67
† LNM Lymph node metastasis; ‡ Overall score calculated as (intensity score) plus (p
* Compared with non-tumoral gastric mucosa, p < 0.001.
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patients with both the primary tumor and lymph node
metastatic tumor specimens, GCRG213p was positive in
51 lymph node metastasis specimens and 52 primary
tumor specimens (76.12% vs 77.61%), respectively, which
indicates that elevated GCRG213p expression in lymph
node metastatic tumor is concordant with GCRG213p
expression in primary gastric carcinoma. GCRG213p ex-
pression in lymph node metastases was also associated
with grades of tumor differentiation (p = 0.015), but not
with other clinicopathological parameters (p >0.05).Relation of GCRG213 expression with survival
Follow-up information was available on 175 gastric can-
cer patients for periods ranging from 18 months to
14 years. Overall survival rates are as follows: 91.42%
(1 year), 78.28%% (2 years), 56.57% (3 years), 39.43%
(4 years), and 23.43% (5 years). The median survival rate
is 41 months.
Based on GCRG213p expression in primary tumors,
there was no significant difference in survival between
patients in the GCRG213p negative category compared
with the GCRG213 positive category (X2 = 2.072, p =
0.558). Similarly, no correlation was observed between
GCRG213p expression in lymph node metastasis and
survival (X2 = 3.272, p = 0.195).GCRG213p expression in malignant and normal gastric
mucosal cell lines
Western blotting assays were performed on gastric cancer
cells including SGC-7901, BGC-823 and non-malignant
gastric mucosal cell line GES-1, in order to further
validate the differential expression of GCRG213p. Protein
bands of about 35 kDa were identified. Three cell lines
tested expressed GCRG213p at different levels. GCRG213p
level was found higher in the cancer cell lines than in
GES-1 (Figure 3). This finding matches with the IHC
result reported in this study, i.e., GCRG213p was found
overexpressed in gastric cancer.GCRG213 expression
Overall score‡ PR§ (%)
0-1 2-3 4-5 6
112 0 0 0 0.00
3 18 11 2 91.18 *
1 17 10 0 96.43 *
26 50 21 3 74.00 *
16 40 16 3 78.67 *
16 42 8 1 76.12 *
ercent cells positive score) as described in methods; § PR Positive rate.
Figure 2 Correlation of GCRG213p immunostaining score in primary gastric cancer with tumor differentiation. Overall Score (OS) of
immunostaining is higher in the well-differentiated cancer than that in the poor-differentiated (p = 0.001).
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Methylation-specific PCR (MSP) analyses were performed
on gastric cancer cells and non-malignant gastric mucosal
cell line GES-1, in order to test the L1 promoter methyla-
tion status in these cell lines. Apart from gastric cancer
cell lines SGC-7901 and BGC-823, we also studied gastric
cancer cell line MGC-823, for purpose of providing more
information about L1 methylation in gastric cancer cell
lines. The PCR products amplified with methylated-
specific primers (MSPM) and unmethylated-specific
primers (MSPU) were 116-bp and 111-bp, respectively. In
GES-1 cells, PCR product was amplified with MSPM, but
not with MSPU, suggesting that L1 promoters in GES-1
cells underwent complete methylation; In SGC-7901 cells,
BGC-823 cells and MGC-803 cells, the corresponding
bands can be amplified with both MSPM and MSPU, indi-
cative of partial methylation (Figure 4).
Bioinformatic identification of GCRG213p as a member of
L1-EN family
BLASTP program analysis, as mentioned above, revealed
that GCRG213p peptide shared 83.0% alignment with theFigure 3 Western blotting analysis of whole cell extract from
gastric malignant and non-malignant cells using anti-
GCRG213p antibody. Cells express GCRG213p with protein bands
of 35-kDa. 1:GES-1,2:SGC-7901;3:BGC-823. The filter was reprobed
with anti-β-actin antibody to control for equal loading
(bottom panel).C-terminal region of L1-EN. Conserved Domain Search of
GCRG213p sequence in the Conserved Domain Database
of NCBI hits the large exonuclease/endonuclease/phos-
phatase (EEP) superfamily, including endonuclease domain
of the non-LTR retrotransposon LINE-1, exonuclease III
(ExoIII)-like apurinic/apyrimidinic (AP) endonucleases, etc.
Further analysis using BLASTP indicates that there are
in GCRG213p sequence some residues which are
important for the conserved features of L1-EN, such as
putative phosphate binding site [ion binding site] (Y115/
N145/H230), putative metal binding site [ion binding
site] (D229) and putative catalytic site [active site]
(Y115/D145/N147/D229/H230) (Figure 5).
Discussion
It is clear that L1 retrotransposition events have oc-
curred in somatic and germ cells. Despite the fact that
full length L1 mRNAs are certainly the dominant source
of L1 retrotransposition, endogenous L1 ORF2 splice
variants with potential biological relevance are found
expressed in different somatic tissues. Belancio etc. [20]
detected SpORF2 transcript in various adult human
tissues and the expression of SpORF2 mRNA exhibits
tissue-specific variation. Thus, L1 function is unlikely to
be limited only to fully active elements. The SpORF2
can also produce functional ORF2 protein. Most non-
LTR retrotransposons are APE-type non-LTR retrotrans-
posons [29]. The crystal structure analyses of the human
L1-EN indicate that it is a prototype for AP-like retro-
transposon encoded endonucleases, which nick DNA
with variable specificity and are responsible for millions
of retrotransposon insertions in eukaryotic genomes
[30]. Both APE1 and L1-EN belong to the large EEP
superfamily that shares the same protein scaffold and
the same catalytic residues.
Considering the fact that GCRG213p shares high se-
quence alignments with L1-EN, and possesses conserved
residues which are crucial for L1-EN phosphate binding,
Figure 4 Methylation-specific PCR (MSP) analysis of LINE-1. Agarose gel electrophoresis of MSP products. M: product amplified with
methylated-specific primer; U: product amplified with unmethylated-specific primer. PC: positive control, human methylated DNA standard; W:
double distilled water control. Note that the GES-1 samples solely show methylated PCR products, while the MGC-803, SGC-7901 and BGC-823
samples show both methylated and unmethylated PCR products.
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GCRG213 is a spliced L1-ORF2. GCRG213p could be a
functional member of L1-EN family, a variant of L1-EN.
The overexpression of L1 in tumors has been widely
presented [12-14]. The cellular endogenous L1-RT emerges
as a constitutive functional component in tumorigenic
cells characterized by a high proliferation and a low differ-
entiation status [31,32]. However, there are few detailed
surveys of L1-EN in human tumor. Ergun etc. used anti-
L1-EN antibody to detect the L1-ORF2 in adult human
tissues, they found strong ORF2p expression in endo-
thelial cells of blood vessels in normal human prostate,
urinary bladder and testicular tissue, but no ORF2p
expression was observed in the cancer cells studied [33].
Oricchio etc. [34] reported that stable L1 RNA interfer-
ence could reduce proliferation and promote differenti-
ation in A-375 melanoma cells. They also observed a
reduction of L1-ORF2 protein. But the researchers have
not identified whether the proliferation effects were from
L1-EN and/or L1-RT. To date, there is no report found
about the role of L1-EN on cell proliferation and differen-
tiation. In this study, we reconfirmed that GCRG213p
expression was elevated in gastric cancer at protein level,
both in the cell model and the tissue sections studied,
which is consistent with our previous study results at
mRNA level [22]. L1 undergo hypomethylation in aFigure 5 Alignment of GCRG213p and L1-EN. Red font represents high
contained residues (arrowed) that are important for the endonuclease activvariety of tumor tissues, including gastric cancer [35].
Shigaki etc. [36] used bisulfite-pyrosequencing technology
to quantify L1 methylation status in resected gastric can-
cer specimens. They found that patients underwent L1
hypomethylation experienced significantly shorter overall
survival than those with hypermethylation. We found in
this study that L1 was completely methylated in normal
gastric mucosa cell line GES-1, but was partially methy-
lated in gastric cancer cell lines. These results correlate
with the GCRG213p expression pattern in gastric cancer
cell lines, thus, provide more evidence regarding the
nature of the GCRG213 peptide. However, we could not
identify a correlation between GCRG213p expression and
survival in this study. Intraepithelial neoplasia is believed to
be a key step of malignant transformation of gastric adeno-
carcinoma, overexpression of GCRG213p in these glands
implied a potential role of GCRG213p in gastric oncoge-
nesis. The high immunostaining score of GCRG213p in
well-differentiated gastric cancer indicated that it might be
involved in gastric cancer differentiation.
While chronic atrophic gastritis is believed to be an
age-related entity, intestinal metaplasia was considered
evidence of atrophic gastritis, since specialized glands
had been replaced by intestinal crypts, so intestinal
metaplasia was considered as age-related. Age plays an
important factor governing the development of gastricconsensus, blue or black font represents low consensus. GCRG213p
ity of L1-EN.
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metaplasia were significantly older than those without
metaplasia [37]. Intestinal metaplasia glands displayed
extensive GCRG213p immunostaining in this study. Mean-
while, we observed that the positive rate of GCRG213p in
gastric cancer tissues in the aged group was higher than
that in the non-aged group. These might imply that
GCRG213p is associated with gastric mucosa aging and
age-related entities. There is no study on the association
between L1 expression and age at present, but average L1
methylation did not vary over time [38,39]. It is believed
that nicking of genomic DNA by the L1-EN can induce
cell toxicity, which results in cell cycle arrest, apoptosis or
senescence. Expression of exogenous full-length L1 and
SpORF2 in normal human fibroblasts, cancer cells and
adult stem cells have led to detectable DNA damage and
resulted in the senescence-like phenotype [20]. Thus, we
suspect that accumulated activity of GCRG213p, a variant
of L1-EN, may represent a potential source for age-related
cellular transformation, which ultimately contributes to
the cell senescence, or oppositely, to an out-of-controlled
(malignant) cellular proliferation.
Conclusions
In conclusion, it is found that overexpression of
GCRG213p, a variant of L1-EN, is common in both
primary gastric cancer and lymph node metastasis.
There is a correlation between GCRG213p expression
and tumor differentiation (well-differentiated). No cor-
relation was found with other clinicopathological para-
meters. GCRG213p expression pattern in the aged
group and intestinal metasplasia implied its possible role
in gastric mucosa senescence and age-related entities,
which deserves further exploration. The data we present
usefully contribute to our knowledge of CGRG213p for
human normal gastric mucosa and malignancies. These
findings provide evidence of somatic L1 expression in
gastric cancer, and shed light on its potential conse-
quences in the form of tumor.
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